Biocon Limited — PPTs, 01-06-2026: Investor Presentation

Here's a concise summary of Biocon's investor presentation:

**Business Performance:** Biocon Group reported strong performance in FY26, with overall revenue reaching ₹16,927 Cr, a 10.9% year-over-year increase. Biosimilars were a key growth driver, surging 15.7% to ₹10,431 Cr and now account for 60% of total revenue. EBITDA stood at ₹3,798 Cr, with margins at 22%.

**Growth Drivers or Strategy:** A core strategy is the ongoing integration of its Generics and Biosimilars businesses to unlock value and expand global access to affordable therapies. The company is also leveraging its CRDMO services, capitalizing on increasing industry outsourcing and its strong market position.

**Recent Developments:** Significant deleveraging efforts include refinancing acquisition loans and a ₹4,500 Cr QIP, projected to save ₹300 Cr annually in interest costs. Major manufacturing capacity investments are largely complete, positioning Biocon for future demand without significant new capex in FY27-28. The company also has strong launch momentum, with multiple new biosimilars and GLP-1s slated for global rollout in 2026.

**Management Commentary / Outlook:** Management anticipates new launches, operating leverage, and consolidation synergies to further improve margin profiles, reinforcing Biocon's strong position for future growth and enhanced liquidity.